secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-11-06T22:28:31+00:00
Accession:  0001493152-26-050541
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity Q3 revenue falls to $1.1M; net loss widens to $5.3M despite CyPath unit sales doubling
--------------------------------------------------------------------------------

- Q3 2026 total revenue was ~$1.1M vs ~$1.4M a year ago; CyPath Lung testing revenue for the first nine months rose 79% to ~$1.1M.
- Net loss was ~$5.3M vs ~$5.1M in Q3 2025; operating loss widened to ~$3.5M from ~$2.3M, with operating expenses ~$4.6M vs ~$3.7M.
- CyPath Lung unit sales rose 100% through Q3 vs the first nine months of 2025; ordering physicians increased 89% YoY and existing-physician volume rose 48%.
- Cash was ~$2.6M at Sept. 30 vs ~$6.4M at Dec. 31, 2025; the company raised $8.0M gross in August and October 2026 offerings, including ~$4.0M after quarter-end.
- Signed an AvMEDICAL distribution agreement targeting VA/government channels; 11 clinical trial sites are active, including nine VA/military centers; patent portfolio has 22 awarded and 36 pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226050541/0001493152-26-050541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226050541/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-050541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer